{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:02:47Z","timestamp":1787504567936,"version":"build-2736575974"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:00Z","timestamp":1737676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:00Z","timestamp":1737676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-025-01810-1","type":"journal-article","created":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T06:25:14Z","timestamp":1737699914000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Upregulation of CD19 by low\u2010dose chidamide promotes CAR T cells functionality in B-cell non-Hodgkin lymphoma"],"prefix":"10.1007","volume":"16","author":[{"given":"Ying","family":"Ni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaochen","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuchun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiguang","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aibin","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,24]]},"reference":[{"key":"1810_CR1","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/S0140-6736(16)32407-2","volume":"390","author":"JO Armitage","year":"2017","unstructured":"Armitage JO, Gascoyne RD, Lunning MA, Cavalli F. Non-Hodgkin lymphoma. Lancet. 2017;390:298\u2013310.","journal-title":"Lancet"},{"key":"1810_CR2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k3204","volume":"362","author":"AA Bowzyk","year":"2018","unstructured":"Bowzyk AA, Ajithkumar T, Behan S, Hodson DJ. Non-Hodgkin lymphoma. BMJ Brit Med J. 2018;362: k3204.","journal-title":"BMJ Brit Med J"},{"key":"1810_CR3","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1038\/bjc.2015.94","volume":"112","author":"A Smith","year":"2015","unstructured":"Smith A, Crouch S, Lax S, Li J, Painter D, Howell D, et al. Lymphoma incidence, survival and prevalence 2004\u20132014: sub-type analyses from the UK\u2019s Haematological Malignancy Research Network. Brit J Cancer. 2015;112:1575\u201384.","journal-title":"Brit J Cancer"},{"key":"1810_CR4","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.6004\/jnccn.2014.0125","volume":"12","author":"AD Zelenetz","year":"2014","unstructured":"Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, et al. Non-Hodgkin\u2019s lymphomas, version 4.2014. J Natl Compr Canc Netw. 2014;12:1282\u2013303.","journal-title":"J Natl Compr Canc Netw"},{"key":"1810_CR5","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1097\/CCO.0000000000000209","volume":"27","author":"C Sarkozy","year":"2015","unstructured":"Sarkozy C, Coiffier B. Primary refractory diffuse large B cell lymphoma in the rituximab era. Curr Opin Oncol. 2015;27:377\u201383.","journal-title":"Curr Opin Oncol"},{"key":"1810_CR6","first-page":"802","volume":"14","author":"ML Davila","year":"2016","unstructured":"Davila ML, Brentjens RJ. CD19-targeted CAR T cells as novel cancer immunotherapy for relapsed or refractory B-cell acute lymphoblastic leukemia. Clin Adv Hematol Onc. 2016;14:802\u20138.","journal-title":"Clin Adv Hematol Onc"},{"key":"1810_CR7","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. New Engl J Med. 2017;377:2531\u201344.","journal-title":"New Engl J Med"},{"key":"1810_CR8","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1016\/j.ymthe.2017.07.004","volume":"25","author":"JN Kochenderfer","year":"2017","unstructured":"Kochenderfer JN, Somerville R, Lu T, Yang JC, Sherry RM, Feldman SA, et al. Long-duration complete remissions of diffuse large B Cell lymphoma after anti-CD19 chimeric antigen receptor T cell therapy. Mol Ther. 2017;25:2245\u201353.","journal-title":"Mol Ther"},{"key":"1810_CR9","first-page":"372","volume":"16","author":"NN Shah","year":"2019","unstructured":"Shah NN, Fry TJ. Mechanisms of resistance to CAR T cell therapy. Nat Rev Clin Oncol. 2019;16:372\u201385.","journal-title":"Nat Rev Clin Oncol"},{"key":"1810_CR10","doi-asserted-by":"publisher","first-page":"5627","DOI":"10.2147\/OTT.S198567","volume":"12","author":"S Li","year":"2019","unstructured":"Li S, Xue L, Wang M, Qiang P, Xu H, Zhang X, et al. Decitabine enhances cytotoxic effect of T cells with an anti-CD19 chimeric antigen receptor in treatment of lymphoma. Oncotargets Ther. 2019;12:5627\u201338.","journal-title":"Oncotargets Ther"},{"key":"1810_CR11","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1038\/s41409-021-01230-z","volume":"56","author":"C Qu","year":"2021","unstructured":"Qu C, Song Y, Yin J, Ma Y, Kang L, Li Z, et al. Decitabine may improve CAR-T efficacy in refractory\/relapsed acute leukemia patients carrying TP53 alterations. Bone Marrow Transpl. 2021;56:1710\u20133.","journal-title":"Bone Marrow Transpl"},{"key":"1810_CR12","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/s41467-020-20696-x","volume":"12","author":"Y Wang","year":"2021","unstructured":"Wang Y, Tong C, Dai H, Wu Z, Han X, Guo Y, et al. Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via epigenetic reprogramming. Nat Commun. 2021;12:409.","journal-title":"Nat Commun"},{"key":"1810_CR13","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1002\/hon.3088","volume":"41","author":"HY Cao","year":"2023","unstructured":"Cao HY, Li L, Xue SL, Dai HP. Chidamide: Targeting epigenetic regulation in the treatment of hematological malignancy. Hematol Oncol. 2023;41:301\u20139.","journal-title":"Hematol Oncol"},{"key":"1810_CR14","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1093\/annonc\/mdv237","volume":"26","author":"Y Shi","year":"2015","unstructured":"Shi Y, Dong M, Hong X, Zhang W, Feng J, Zhu J, et al. Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma. Ann Oncol. 2015;26:1766\u201371.","journal-title":"Ann Oncol"},{"key":"1810_CR15","doi-asserted-by":"publisher","first-page":"16015","DOI":"10.1038\/mto.2016.15","volume":"3","author":"X Wang","year":"2016","unstructured":"Wang X, Riviere I. Clinical manufacturing of CAR T cells: foundation of a promising therapy. Mol Ther-Oncolytics. 2016;3:16015.","journal-title":"Mol Ther-Oncolytics"},{"key":"1810_CR16","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.immuni.2019.12.011","volume":"52","author":"PS Hegde","year":"2020","unstructured":"Hegde PS, Chen DS. Top 10 challenges in cancer immunotherapy. Immunity. 2020;52:17\u201335.","journal-title":"Immunity"},{"key":"1810_CR17","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","volume":"396","author":"JS Abramson","year":"2020","unstructured":"Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396:839\u201352.","journal-title":"Lancet"},{"key":"1810_CR18","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","volume":"20","author":"FL Locke","year":"2019","unstructured":"Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial. Lancet Oncol. 2019;20:31\u201342.","journal-title":"Lancet Oncol"},{"key":"1810_CR19","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. New Engl J Med. 2019;380:45\u201356.","journal-title":"New Engl J Med"},{"key":"1810_CR20","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1002\/ajh.26301","volume":"96","author":"JR Westin","year":"2021","unstructured":"Westin JR, Kersten MJ, Salles G, Abramson JS, Schuster SJ, Locke FL, et al. Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed\/refractory aggressive B-cell lymphomas: observations from the JULIET, ZUMA-1, and TRANSCEND trials. Am J Hematol. 2021;96:1295\u2013312.","journal-title":"Am J Hematol"},{"key":"1810_CR21","first-page":"4921","volume":"24","author":"HH Cao","year":"2020","unstructured":"Cao HH, Wang LL, Geng CK, Mao WW, Yang LL, Ma Y, et al. Therapeutic effects of chimeric antigen receptor T cells (CAR-T) on relapse\/refractory diffuse large B-cell lymphoma (R\/R DLBCL): a meta-analysis. Eur Rev Med Pharmaco. 2020;24:4921\u201330.","journal-title":"Eur Rev Med Pharmaco"},{"key":"1810_CR22","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1002\/cac2.12313","volume":"42","author":"Y Xu","year":"2022","unstructured":"Xu Y, Li P, Liu Y, Xin D, Lei W, Liang A, et al. Epi-immunotherapy for cancers: rationales of epi-drugs in combination with immunotherapy and advances in clinical trials. Cancer Commun. 2022;42:493\u2013516.","journal-title":"Cancer Commun"},{"key":"1810_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.750323","volume":"11","author":"W Liu","year":"2021","unstructured":"Liu W, Zhao D, Liu T, Niu T, Song Y, Xu W, et al. A multi-center, real-world study of chidamide for patients with relapsed or refractory peripheral T-cell lymphomas in China. Front Oncol. 2021;11: 750323.","journal-title":"Front Oncol"},{"key":"1810_CR24","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1002\/hon.2979","volume":"40","author":"Y Wang","year":"2022","unstructured":"Wang Y, Xue H, Song W, Xiao S, Jing F, Dong T, et al. Chidamide with PEL regimen (prednisone, etoposide, lenalidomide) for elderly or frail patients with relapsed\/refractory diffuse large B-Cell lymphoma -results of a single center, retrospective cohort in China. Hematol Oncol. 2022;40:617\u201325.","journal-title":"Hematol Oncol"},{"key":"1810_CR25","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/s41419-019-2210-0","volume":"11","author":"XW Guan","year":"2020","unstructured":"Guan XW, Wang HQ, Ban WW, Chang Z, Chen HZ, Jia L, et al. Novel HDAC inhibitor Chidamide synergizes with Rituximab to inhibit diffuse large B-cell lymphoma tumour growth by upregulating CD20. Cell Death Dis. 2020;11:20.","journal-title":"Cell Death Dis"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-01810-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-01810-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-01810-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T06:25:17Z","timestamp":1737699917000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-01810-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,24]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1810"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-01810-1","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,24]]},"assertion":[{"value":"18 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"84"}}